Cure Pharma to buy cannabinoid pipeline and uplist to NASDAQ
Cure Pharmaceuticals says it plans to apply its drug delivery technologies to Therapix Biosciences’ cannabinoid-based drug pipeline for non-pain indications.
Top Headlines
Global Industry News
-
US FDA targets endpoints, preclinical testing and trial design to advance gene therapies
from Outsourcing-Pharma.com
-
Catalent brings in Berkeley Lights to optimise cell lines
from BioPharma-Reporter.com
-
Bracket owner Genstar Capital to acquire CRF Health and combine companies
from Outsourcing-Pharma.com
-
Targeting special patient populations with the help of AI
from Outsourcing-Pharma.com
Hot Topics
-
AMW owners sell up to YF Capital and Hybio Pharma
Globalisation
-
Nearly half of companies unprepared for Brexit, finds EMA survey
Globalisation
-
Recipharm anticipates FMD compliance struggles, launches standalone service
Globalisation
-
Bain Capital buys DSM Sinochem Pharmaceuticals, ‘fully supports’ API biz
Mergers and acquisitions
